17,261 trials
Cutaneous Squamous Cell Carcinoma
Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Depression · Depressive Disorder · Depression, Postpartum
Primary: Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score — -13.0; -12.0; -14.0; -14.3 Scores on a scale
Multiple Myeloma
Primary: Percentage of Participants With Very Good Partial Response (VGPR) or Better (Complete Response + VGPR) — 32.2 percentage of participants
Schizophrenia Schizoaffective
Primary: Participants With at Least One Treatment Emergent Adverse Event (TEAE). — 10; 8; 18; 1 Number of Participants with TEAEs
Ulcerative Colitis
Primary: Number of Subjects With Treatment-emergent Adverse Events — 18; 5 Participants — p=0.2096
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 13; 13; 5; 2 participants
Necrobiosis Lipoidica
Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005
Hereditary Angioedema
Primary: Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug (Full Analysis Set) — NA; NA Time (h) — p=0.0010
Non-Cystic Fibrosis Bronchiectasis
Primary: Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period — NA; NA; 189.0 days — p== 0.014
Soft Tissue Sarcoma, Adult · Soft Tissue Sarcoma, Child
Primary: Number of Participants With at Least One Severe or Life-Threatening Adverse Event — 1 Participants
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Atopic Dermatitis
Primary: Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12 — -5.896; -15.604; -0.729; -0.506 Fold change
Gastric Cancer · GastroEsophageal Cancer
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAE) — 61; 19 Participants
Hematologic Malignancies · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Cumulative Incidence of Grade II to IV aGvHD Through Day +100 Based on Investigator Assessment — 42.9; 44.4; 24.9 percentage of…